Leqembi (lecanemab-irmb) is an FDA-approved prescription injection indicated for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.
Leqembi (lecanemab-irmb) is a prescription medicine used to treat people with Alzheimer’s disease. It is an amyloid beta-directed antibody indicated for patients with mild cognitive impairment or mild dementia stages of the disease. Leqembi is administered via intravenous infusion and works by reducing amyloid beta plaques in the brain, a defining pathophysiology of Alzheimer's disease.
Developed and marketed by Eisai Inc., Leqembi represents a significant advancement in Alzheimer's treatment. Patients must confirm the presence of amyloid beta pathology prior to treatment. The medication requires monitoring for Amyloid Related Imaging Abnormalities (ARIA) through MRI scans. Support and financial assistance programs are available through Eisai Patient Support to help eligible patients access this therapy.
Latest manuals from manuals+ curated for this brand.
Common questions about manuals, registration, and support for this brand.
Leqembi is indicated for the treatment of Alzheimer’s disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.
The recommended dosage is 10 mg/kg administered as an intravenous infusion over approximately one hour, once every two weeks.
You can contact Eisai Inc. at 1-888-274-2378 or the FDA at 1-800-FDA-1088 to report suspected adverse reactions.
According to the prescribing information, there are no listed contraindications for the use of Leqembi.
The most common adverse reactions reported include infusion-related reactions, headache, and ARIA-edema.